Business Wire

Colt harnesses ADVA FSP 3000 for quantum-secured transport in live network trial

16.2.2021 11:00:00 EET | Business Wire | Press release

Share

ADVA (FSE: ADV) today announced that Colt Technology Services has successfully conducted a field trial of quantum-secured transport using its FSP 3000 platform with ConnectGuard™ Layer 1 encryption technology. The trial utilized quantum key distribution (QKD) to super-encrypt live data traffic, demonstrating how mission-critical services can be protected even against large-scale attacks. Conducted over Colt’s deployed metro network in Frankfurt, the demo shows how enterprise customers can achieve secure cloud access and robustly protect sensitive data in the long term. ADVA’s partner ID Quantique also played a key role in the trial.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210216005179/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

ADVA’s ConnectGuard™ technology helps Colt showcase the future of quantum-safe networking (Photo: Business Wire)

“With quantum computers on the horizon, it’s crucial to stay one step ahead of the hackers. This trial is a major step towards the next generation of cryptographic infrastructure and takes us closer to safeguarding our customers’ information from tomorrow’s threats,” said Oktay Tekin, director, sales engineers, DACH, Colt Technology Services. “Businesses across the world depend on the speed, reliability and robust security of our services to operate effectively and with complete peace of mind. By conducting this trial with ADVA to harness QKD technologies, we’re exploring how to protect against unprecedented challenges further down the line.”

Widely predicted to be vital to the future of network security, QKD offers the ultimate defense against eavesdropping attacks. Using the laws of physics to create tamper-proof encryption keys, it protects traffic from all threats, including data harvesting for future quantum hacking. Colt’s trial harnessed the ADVA FSP 3000, which receives quantum keys generated by ID Quantique’s QKD technology. The QKD provides quantum random bit strings. These keys are used as an additional entropy source for the ADVA encryption solution, operating at line speeds of 100Gbit/s. The solution is the first commercial high-speed optical networking product to feature a dedicated interface for quantum keys based on the ETSI key delivery standard.

“Our FSP 3000 ConnectGuard™ encryption solution ensures maximum security as well as high capacity and low latency. In recent years, it has won a fierce reputation for protecting service provider and enterprise networks across the globe. Now, this trial of QKD-secure transport is proving how vital our technology will be even in the post-quantum era,” commented Uli Schlegel, director, product line management, ADVA. “Colt’s trial shows that it’s now possible to secure high-speed connectivity over deployed operational networks against tomorrow’s quantum computer attacks. It’s a significant milestone for Colt’s enterprise customers. From sensitive financial information to valuable intellectual property, their data will soon be shielded from the cybercriminals of the future.”


About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.

About Colt
Colt strives to transform the way the world works through the power of connectivity - taking what’s always been in its DNA to enable customers’ success. The Colt IQ Network connects more than 900+ data centres and over 29,000 on net buildings across Europe, Asia and North America’s largest business hubs. Colt understands today’s shifting connectivity requirements and provides agile, on-demand and secure high bandwidth networking and voice solutions to ensure enterprises can thrive. Customers include data-intensive organisations spanning over 210 cities in more than 30 countries. Colt is a recognised innovator and pioneer in Software Defined Networks (SDN) and Network Function Virtualisation (NFV). Privately owned, Colt is one of the most financially sound companies in the sector, and because of this, it’s able to put its customers’ needs at its core. For more information, please visit www.colt.net.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com

For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 16:00:00 EEST | Press release

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's core mission has always been to increase access to life-saving treatments. It’s about getting the right information to the right care tea

Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 16:00:00 EEST | Press release

Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become operational infrastructure without corresponding security maturity. The report also reveals that AI environments are rapidly becoming more interconnected and business critical. Among organizations adopting AI, 64% now run vector databases, 55

Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 16:00:00 EEST | Press release

As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructure to monitor airspace activity. The new 86,350-square-foot facility is a major step in readying supply for multiple, large, global markets. The

SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 15:51:00 EEST | Press release

The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/

Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus ® (ocrelizumab) for Multiple Sclerosis9.7.2026 15:45:00 EEST | Press release

Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260709701277/en/ “This agreement reflects our focus on pushing high-quality biologics to the finish line efficiently and at scale,” said Anjan Selz, Chief Executive Officer of Polpharma Biologics International AG. “Teva brings reach, discipline and real commercial strength to our strategic collaboration. Combining its global footprint with our technical and develo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye